In conclusion, a larger number of metastatic organs and PS deterioration are important factors for withholding subsequent chemotherapy after failure of EGFR‐TKI therapy and poor prognosis in EGFR‐mutated NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.